Arrowhead Pharmaceuticals Inc (ARWR) - Total Liabilities
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has total liabilities worth $881.88 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Arrowhead Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Arrowhead Pharmaceuticals Inc - Total Liabilities Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Autoliv Inc
ST:ALIV-SDB
|
Sweden | Skr5.86 Billion |
|
Shoprite Holdings Ltd
JSE:SHP
|
South Africa | ZAC94.83 Billion |
|
Voya Financial Inc
NYSE:VOYA
|
USA | $2.79 Billion |
|
Avantor Inc
NYSE:AVTR
|
USA | $5.97 Billion |
|
Affiliated Managers Group, Inc.
NYSE:AMG
|
USA | $5.20 Billion |
|
Bluescope Steel Ltd
AU:BSL
|
Australia | AU$5.50 Billion |
|
Orkla ASA
OL:ORK
|
Norway | Nkr41.66 Billion |
|
360 Security Technology Inc
SHG:601360
|
China | CN¥8.41 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Arrowhead Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Arrowhead Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arrowhead Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual total liabilities of Arrowhead Pharmaceuticals Inc from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $947.02 Million | -0.18% |
| 2024-09-30 | $948.74 Million | +98.32% |
| 2023-09-30 | $478.39 Million | +74.85% |
| 2022-09-30 | $273.60 Million | -9.20% |
| 2021-09-30 | $301.33 Million | +396.22% |
| 2020-09-30 | $60.72 Million | -42.61% |
| 2019-09-30 | $105.81 Million | +546.40% |
| 2018-09-30 | $16.37 Million | -29.31% |
| 2017-09-30 | $23.16 Million | -30.16% |
| 2016-09-30 | $33.15 Million | +46.39% |
| 2015-09-30 | $22.65 Million | +34.55% |
| 2014-09-30 | $16.83 Million | +45.16% |
| 2013-09-30 | $11.59 Million | +50.21% |
| 2012-09-30 | $7.72 Million | +132.19% |
| 2011-09-30 | $3.32 Million | -22.26% |
| 2010-09-30 | $4.28 Million | +50.35% |
| 2009-09-30 | $2.84 Million | -42.57% |
| 2008-09-30 | $4.95 Million | +45.83% |
| 2007-09-30 | $3.40 Million | +16.30% |
| 2006-09-30 | $2.92 Million | +185.16% |
| 2005-09-30 | $1.02 Million | +48.48% |
| 2004-09-30 | $689.70K | +617.11% |
| 2003-09-30 | $96.18K | -94.04% |
| 2002-09-30 | $1.61 Million | +19.50% |
| 2001-09-30 | $1.35 Million | +13.10% |
| 2000-09-30 | $1.19 Million | +10.75% |
| 1999-09-30 | $1.08 Million | -60.24% |
| 1998-09-30 | $2.71 Million | +1.07% |
| 1997-09-30 | $2.68 Million | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more